123 related articles for article (PubMed ID: 8845865)
1. Individualized dosing of amonafide based on a pharmacodynamic model incorporating acetylator phenotype and gender.
Ratain MJ; Mick R; Janisch L; Berezin F; Schilsky RL; Vogelzang NJ; Kut M
Pharmacogenetics; 1996 Feb; 6(1):93-101. PubMed ID: 8845865
[TBL] [Abstract][Full Text] [Related]
2. Phase I study of amonafide dosing based on acetylator phenotype.
Ratain MJ; Mick R; Berezin F; Janisch L; Schilsky RL; Vogelzang NJ; Lane LB
Cancer Res; 1993 May; 53(10 Suppl):2304-8. PubMed ID: 8485716
[TBL] [Abstract][Full Text] [Related]
3. Paradoxical relationship between acetylator phenotype and amonafide toxicity.
Ratain MJ; Mick R; Berezin F; Janisch L; Schilsky RL; Williams SF; Smiddy J
Clin Pharmacol Ther; 1991 Nov; 50(5 Pt 1):573-9. PubMed ID: 1934870
[TBL] [Abstract][Full Text] [Related]
4. Population pharmacodynamic study of amonafide: a Cancer and Leukemia Group B study.
Ratain MJ; Rosner G; Allen SL; Costanza M; Van Echo DA; Henderson IC; Schilsky RL
J Clin Oncol; 1995 Mar; 13(3):741-7. PubMed ID: 7884434
[TBL] [Abstract][Full Text] [Related]
5. An ECOG phase II study of amonafide in unresectable or recurrent carcinoma of the head and neck (PB390). Eastern Cooperative Oncology Group.
Leaf AN; Neuberg D; Schwartz EL; Wadler S; Ritch PS; Dutcher JP; Adams GL
Invest New Drugs; 1997; 15(2):165-72. PubMed ID: 9220297
[TBL] [Abstract][Full Text] [Related]
6. Amonafide: An active agent in the treatment of previously untreated advanced breast cancer--a cancer and leukemia group B study (CALGB 8642).
Costanza ME; Berry D; Henderson IC; Ratain MJ; Wu K; Shapiro C; Duggan D; Kalra J; Berkowitz I; Lyss AP
Clin Cancer Res; 1995 Jul; 1(7):699-704. PubMed ID: 9816035
[TBL] [Abstract][Full Text] [Related]
7. Bootstrap validation of pharmacodynamic models defined via stepwise linear regression.
Mick R; Ratain MJ
Clin Pharmacol Ther; 1994 Aug; 56(2):217-22. PubMed ID: 8062499
[TBL] [Abstract][Full Text] [Related]
8. Pharmacogenetics of anticancer agents: lessons from amonafide and irinotecan.
Innocenti F; Iyer L; Ratain MJ
Drug Metab Dispos; 2001 Apr; 29(4 Pt 2):596-600. PubMed ID: 11259359
[TBL] [Abstract][Full Text] [Related]
9. Phase II study of amonafide in advanced and recurrent sarcoma patients.
Perez RP; Nash SL; Ozols RF; Comis RL; O'Dwyer PJ
Invest New Drugs; 1992 Jul; 10(2):99-101. PubMed ID: 1500272
[TBL] [Abstract][Full Text] [Related]
10. Phase I clinical investigation of benzisoquinolinedione (amonafide) in adults with refractory or relapsed acute leukemia.
O'Brien S; Benvenuto JA; Estey E; Beran M; Felder TB; Keating M
Cancer Res; 1991 Feb; 51(3):935-8. PubMed ID: 1988134
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of Amonafide in dogs.
Lu K; McLean MA; Vestal ML; Newman RA
Cancer Chemother Pharmacol; 1988; 21(2):134-8. PubMed ID: 3349561
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of amonafide in refractory and relapsing multiple myeloma: a Southwest Oncology Group study.
Hanson KH; Crowley J; Salmon SE; Keppen M; Braun TJ; Bonnet JD
Anticancer Drugs; 1991 Jun; 2(3):247-50. PubMed ID: 1802018
[TBL] [Abstract][Full Text] [Related]
13. Phase II trial of amonafide for the treatment of advanced, hormonally refractory carcinoma of the prostate. A Southwest Oncology Group study.
Marshall ME; Blumenstein B; Crawford ED; Thompson IM; Craig JB; Eisenberger M; Ahmann F
Am J Clin Oncol; 1994 Dec; 17(6):514-5. PubMed ID: 7977172
[TBL] [Abstract][Full Text] [Related]
14. Phase II trial of gallium nitrate, amonafide and teniposide in metastatic non-small cell lung cancer. An Eastern Cooperative Oncology Group study (E2588).
Chang AY; Tu ZN; Smith JL; Bonomi P; Smith TJ; Wiernik PH; Blum R
Invest New Drugs; 1995; 13(2):137-41. PubMed ID: 8617576
[TBL] [Abstract][Full Text] [Related]
15. Phase II study of amonafide in advanced breast cancer.
Scheithauer W; Dittrich C; Kornek G; Haider K; Linkesch W; Gisslinger H; Depisch D
Breast Cancer Res Treat; 1991 Dec; 20(1):63-7. PubMed ID: 1813070
[TBL] [Abstract][Full Text] [Related]
16. Clinical pharmacokinetics of amonafide (NSC 308847) in 62 patients.
Kreis W; Chan K; Budman DR; Allen SL; Fusco D; Mittelman A; Hock K; Akerman S; Calabro A; Puccio C; Spigelman M
Cancer Invest; 1996; 14(4):320-7. PubMed ID: 8689426
[TBL] [Abstract][Full Text] [Related]
17. Phase I clinical investigation of amonafide.
Saez R; Craig JB; Kuhn JG; Weiss GR; Koeller J; Phillips J; Havlin K; Harman G; Hardy J; Melink TJ
J Clin Oncol; 1989 Sep; 7(9):1351-8. PubMed ID: 2549205
[TBL] [Abstract][Full Text] [Related]
18. Amonafide in patients with leiomyosarcoma of the uterus: a phase II Gynecologic Oncology Group study.
Asbury R; Blessing JA; Buller R; Malfetano JH; Walker J; Sevin BU
Am J Clin Oncol; 1998 Apr; 21(2):145-6. PubMed ID: 9537200
[TBL] [Abstract][Full Text] [Related]
19. A phase II trial of amonafide in patients with endometrial cancer: a Gynecologic Oncology Group Study.
Asbury R; Blessing JA; Reid GC; McGuire WP
Am J Clin Oncol; 1998 Aug; 21(4):406-7. PubMed ID: 9708643
[TBL] [Abstract][Full Text] [Related]
20. Phase II trial of amonafide in advanced colorectal cancer: a SouthWest Oncology Group study.
Brown TD; Goodman PJ; Fleming T; Macdonald JS; Craig JB; Einstein AB
Anticancer Drugs; 1993 Feb; 4(1):49-50. PubMed ID: 8457714
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
